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Hirotsu C, Tufik S, Bergamaschi CT, Tenorio NM, Araujo P,
Andersen ML. Sleep pattern in an experimental model of chronic kidney
disease. Am J Physiol Renal Physiol 299: F1379–F1388, 2010. First pub-
lished September 8, 2010; doi:10.1152/ajprenal.00118.2010.—The preva-
lence of sleep disorders is significantly elevated in chronic kidney
disease (CKD) patients. Numerous factors likely contribute to the high
prevalence of sleep problems in uremic patients. The objective of this
study was to evaluate the long-term sleep pattern changes in uremic
rats during disease progression. Sleep recordings of the rats were
monitored during light and dark periods that lasted 12 h each. These
recordings were performed on days 7, 30, 60, and 90 after CKD
induction. Cardiovascular, hormonal, and biochemical changes were
evaluated at these same time points in control and uremic rats. CKD
progression was reflected by the presence of hypertension and pro-
gressive increases in urea, creatinine, and cholesterol levels. We also
observed hormonal fluctuations of corticosterone and ACTH, which
indicated a potential alteration in the hypothalamic-pituitary-adrenal
axis in diseased rats. In addition, rats with CKD demonstrated frag-
mented sleep with a greater number of arousals and decreased sleep
efficiency in the light period during disease progression. In the dark
period, there was an initial increase in sleep efficiency in CKD rats,
but after 90 days of CKD, these animals slept less compared with the
control group. Collectively, these metabolic and cardiovascular
changes were associated with the persistent alterations in sleep archi-
tecture observed in CKD rats.
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CHRONIC KIDNEY DISEASE (CKD) results in profound biochemical
changes that affect numerous organs and regulatory systems,
such as the central nervous system. Patients with uremic
encephalopathy exhibit disorientation, somnolence, and coma
symptoms, among others (26). Additional symptoms include
anorexia, nausea, vomiting (35), sexual dysfunction (41), de-
pression (29, 30), and sleep disorders (28).
The prevalence of sleep disorders is significantly higher (up
to 80%) in patients with chronic renal failure compared with
the general population (22). In the predialysis era, uremia was
associated with “day-night reversal” as a late symptom (24,
25). Sleep disorders associated with CKD may be related to
the effects of uremic toxins on the central nervous system
(18) and may result in excessive daytime sleepiness, insom-
nia, decreased mental acuity, restless legs syndrome, and
sleep apnea (23).
Although poor sleep quality is common in patients with
CKD, the mechanism responsible for this phenomenon has
not been clearly determined. In addition to causing sleep
disruption and sleep loss, these conditions may further
increase the considerable cardiovascular morbidity and mor-
tality of this patient population (43). Thus sleep abnormal-
ities appear to have significant negative effects on quality of
life and functional health status. A more complete under-
standing of the sleep problems associated with CKD is
necessary to improve health outcomes and facilitate re-
search efforts directed at preventing or counteracting CKD-
related sleep disorders.
In our laboratory, we have adopted a widely studied
experimental model of CKD (5/6 nephrectomy) in rats, in
which the associated metabolic and cardiovascular changes
closely resemble those observed in humans. These changes
include hypertension, progressive renal injury, proteinuria,
and nitrosative stress (11, 12, 34, 39, 47). Only one previous
study has evaluated sleep disorders in animal models of
CKD (28). In that study, an indirect evaluation of the
sleep-wake cycle was attained by the punctual measurement
of movements using infrared monitoring. However, this
method does not permit for the complete scoring of sleep
stages, which is essential for an objective assessment of the
sleep-wake cycle.
Renal diseases are devastating illnesses that are associated
with a high morbidity and mortality, and the incidence of renal
failure is growing at a rate of 6–8% per year worldwide (13).
Considering that sleep disorders are common in patients with
CKD and do not receive the clinical and scientific interest they
deserve, it is important to understand the pathogenic mecha-
nisms that govern the initiation and progression of sleep
disorders in CKD using animal models. Despite the availability
of other animal models, rats and mice remain the main species
used by researchers in the fields of nephrology and sleep. Thus
the current study was undertaken to characterize the sleep
architecture of a rat CKD model during different disease stages
to clarify whether the observed sleep pattern mirrors the
changes that occur in humans with chronic renal failure.
Second, we aimed to analyze the cardiovascular, biochemical,
and hormonal alterations that occurred during disease progres-
sion and to correlate these alterations with possible changes in
the sleep architecture.
MATERIALS AND METHODS
Animals
This study was performed using adult male Wistar rats (250–350 g)
that were bred in the animal facility of CEDEME (UNIFESP). The
rats were maintained in a temperature-controlled room (23  1°C)
with a 12:12-h light-dark cycle (lights on at 7:00 A.M.) and free
access to food and water in standard polypropylene cages. All of the
procedures used in the present study complied with the Ethical and
Practical Principles of the Use of Laboratory Animals (4), and the
experimental protocol was approved by the Ethical Committee of
UNIFESP (no. 1848/08).
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Experimental Protocol
For the cardiovascular and biochemical experiments (Fig. 1A), after
disease induction (day 0), the CKD group (n  46) was distributed
into five subgroups according to disease duration: CKD30 (30 days,
n  10), CKD60 (60 days, n  10), CKD90 (90 days, n  10),
CKD120 (120 days, n  8), and CKD150 (150 days, n  8). The
control (CTRL) group (n  15) was simultaneously evaluated at the
same time points (3 animals for each time point). For the sleep pattern
study (Fig. 1B), after disease induction and electrode implantation
(day 0), the CKD group (n  32) was distributed into four subgroups
according to disease duration: CKD7 (7 days, n  8), CKD30 (30
days, n  8), CKD60 (60 days, n  8), and CKD90 (90 days, n  8).
The CTRL group (n  12) was simultaneously evaluated at the same
time points (3 animals for each time point). We elected to interrupt the
sleep recording at CKD90 because only a few animals survived after
90 days, and the sleep record quality was compromised.
Induction of CKD
The animals were randomly assigned to either the CTRL or the
CKD group. In the CKD model, the right kidney was removed, and an
infarction of 2/3 of the left kidney was achieved through the ligature
of two of the major branches of the left main renal artery, as described
elsewhere (52). The CTRL group did not undergo a mock surgery, but
they received anesthesia equivalent to the CKD group. The procedures
were conducted under ketamine and xylazine anesthesia (40 mg/kg
and 20 mg/kg body wt, respectively, ip) using strict hemostasis and
aseptic techniques. After the surgery, both the CTRL and CKD rats
received penicillin (20,000 U in 0.1 ml im), sodium diclofenac (25
mg/ml ip), and ibuprofen (50 mg/ml vo). We elected not to perform
the mock surgery because of the quick recovery of rats from this
procedure, which made this surgery unnecessary and unhelpful for the
chronic parameters evaluated in the current study. However, we
acknowledge the lack of a sham surgery control as a limitation of this
study.
Stereotaxic Surgery
For the sleep pattern protocol, immediately after renal ablation,
stereotaxic surgery was performed to implant electrodes and to assess
the sleep-wake cycles of the rats. While under deep anesthesia, the
rats were mounted in a classical stereotaxic frame (Insight Instru-
ments). Two bipolar electrodes with four stainless-steel screws (ø 0.9
mm) were placed in the skull through small holes that had been bored
in the right lateral frontoparietal region (1 pair) to monitor the bipolar
electrocorticogram (ECoG). Two nickel-chromium flexible wires
were inserted in the neck muscles to record the electromyogram
(EMG). All of the rats received penicillin (20,000 U in 0.1 ml im),
sodium diclofenac (25 mg/ml ip), and ibuprofen (50 mg/ml vo) after
surgery. After surgery (5 days), the sockets were connected via
flexible recording cables and a commutator to a polygraph and
computer. The rats habituated to the apparatus for 2 days, at which
point their 24-h acute sleep-wake states (7 days after the CKD
induction surgery) were recorded. The sleep-wake records were per-
formed at 7, 30, 60, and 90 days after the surgery in the different
subgroups.
Sleep Recording
The recordings were performed on a Nihon Koden (TYO) model
QP-223A apparatus using three channels for each animal. The ECoG
signals were amplified and filtered with a low-pass filter at 0.5 Hz and
a higher cut-off of 35 Hz because the EEG frequency band between
0.5 and 30 Hz has the most clinical relevance in the conscious state.
The EMG activity was filtered with a low-pass filter at 5.3 Hz because
this allows for the recording of the fast range of frequencies (1, 3, 49,
50 51). Sleep recordings were monitored during light and dark periods
that lasted 12 h each and were evaluated on days 7, 30, 60, and 90
after the CKD induction or assignment to the CTRL group. During the
experimental period, the rats were maintained in their own cage inside
a Faraday chamber. The ECoG traces were visually and manually
identified and scored according to Timo-Iaria et al. (53). The follow-
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Fig. 1. Experimental protocol. Time lines for the cardiovascular and biochemical protocol (A) and the sleep pattern protocol (B) are shown. CTRL, control
animals; CKD, chronic kidney disease animals; MAP, mean arterial pressure acquisition; HR, heart rate acquisition.
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ing sleep parameters were assessed: sleep efficiency (the total sleep
time percentage during the recording time), slow-wave sleep (the
deep sleep time percentage throughout the recording), paradoxical
sleep [the sleep stage also called rapid-eye movement (REM)
sleep, which presents an EEG pattern similar to waking, despite
muscle atonia], and arousals (events with a duration of at least 15
s and comprising an abrupt modification of the baseline ECoG
frequency and the high-amplitude EMG activity followed by slow-
wave sleep, expressed as absolute numbers).
Clinical and Cardiovascular Evaluations
The clinical and cardiovascular data included body weight, heart
rate (HR), and mean arterial pressure (MAP), which were measured in
subgroups CKD30, CKD60, CKD90, CKD120, and CKD150 and
their respective CTRL groups. After the disease induction period, all
of the animals were anesthetized with halothane (2%) using an
anesthesia vaporizer. While the rats were breathing spontaneously, we
inserted a femoral arterial catheter constructed from PE-50 and PE-10
tubing and filled with saline for the MAP and HR recordings. After
surgery, the rats were placed in their home cages to recover for 2 h.
The experiments were performed using conscious animals.
Blood Samples for Biochemical and Hormonal Evaluations
After the invasive measurement of blood pressure (1 day), animals
from each group were killed by decapitation with minimum discom-
fort between 9:00 and 11:00 A.M. Three rats from the CTRL group
were decapitated each day together with those from the CKD groups.
Blood was collected in glass tubes and centrifuged to obtain serum or
plasma samples. Renal function and lipid profiles were assessed by
measuring the concentrations of serum urea, creatinine, sodium and
potassium electrolytes, triglyceride, total cholesterol, and fractions
using an automated colorimetric method (ADVIA 1650; BAYER
Diagnostics) (5, 7). Hormonal profiles were evaluated based on
plasma corticosterone and ACTH levels (6). Corticosterone concen-
trations were assayed with a double-antibody radioimmunoassay
method using a commercial kit that is specific for rats (MP Biomedi-
cals). The sensitivity of the assay was 0.25 ng/ml. The ACTH
concentrations were determined according to a sequential chemilumi-
nescence immunometric method using a monoclonal murine antibody
that is specific for ACTH (DPC Immulite). The sensitivity of the assay
was 5 pg/ml.
Statistical Methods
Data are expressed as means SD. To analyze the parametric data,
ANOVA followed by Duncan’s test was used. To analyze the non-
parametric data, the Kruskal-Wallis test followed by the Games-
Howell post hoc test was used. A correlation analysis (Spearman’s
coefficient) was used for the univariate analysis of data from the sleep
recording experiment [CTRL (n  8) and CKD (n  32) rats that had
undergone MAP measurements and blood collection for biochemical
and hormonal analysis]. After the correlation analysis, a multiple
linear regression was applied to identify the possible determinants of
sleep disorders. All variables with a significance of at least 0.01 in the
univariate analysis (correlation analysis) were included in the multiple
linear regression model. The level of statistical significance was set at
P  0.05.
RESULTS
Body Weight
A significant weight gain was observed in both groups from
the fourth time point onward (P  0.05). A decrease in body
weight was detected in the CKD group compared with the
CTRL during only the 2nd and 18th weeks of evaluation
(Fig. 2).
MAP and HR
The Kruskal-Wallis test revealed (P  0.001) an increase in
the MAP in all of the CKD groups compared with CTRL (P 
0.05) (Fig. 3A). An analysis of the HR values using the
Kruskal-Wallis test also revealed significant differences among
the groups (P  0.0001); an increase in HR was observed only
Fig. 2. Body evolution. Time course of body weight in CTRL and CKD
groups. Values are expressed as means  SD. *P  0.01 compared with
CTRL. #P  0.05 compared with baseline values of the respective group.
Fig. 3. Cardiovascular evaluation. MAP (A) and HR (B) in CTRL and CKD
groups at different disease time points. CKD30, -60, -90, -120, and -150
indicate 30, 60, 90, 120, and 150 days of CKD, respectively. Values are
expressed as means  SD. *P  0.05 compared with CTRL.
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in CKD30 and CKD150 compared with CTRL (P 0.05) (Fig.
3B). Despite the significant differences, the HR values deter-
mined for all of the groups were within the normal range,
which indicated an absence of tachycardia.
Renal Function
The Kruskal-Wallis test revealed (P  0.0001) an increase
in serum urea concentrations in CKD90, CKD120, and
CKD150 compared with CTRL (P  0.01) (Fig. 4A). Signif-
icant differences in serum creatinine concentrations were also
determined among the groups (P  0.0001); an increase was
detected in CKD90, CKD120, and CKD150 compared with
CTRL (P  0.05). A significant difference in the serum
creatinine concentration was also observed between CKD30
and CKD150 (P  0.05) (Fig. 4B). Between-group differences
in serum concentrations of sodium (Fig. 4C) and potassium
(Fig. 4D) were not statistically significant (P  0.05).
Lipid Profile
The analysis of the triglyceride concentration by one-way
ANOVA revealed a group effect (P  0.001); triglyceride
levels were increased in CKD90 compared with all other
groups (P 0.05) (Fig. 5A). Total cholesterol was analyzed by
the Kruskal-Wallis test, which revealed significant differences
among the groups (P  0.0001); a significant increase was
observed in CKD60 to CKD150 compared with CTRL (P 
0.05). The CKD90 and CKD120 groups also differed from
CKD30 (P  0.01), and groups CKD30 to CKD120 differed
statistically from CKD150 (P  0.01) (Fig. 5B). One-way
ANOVA revealed a group effect (P  0.001); a significant
increase in high-density lipoprotein (HDL) cholesterol was
observed in groups CKD60 to CKD150 compared with CTRL
(P  0.001). CKD30 and CKD90 also differed statistically
from CKD120 (P  0.001), and CKD150 differed from
CKD30, CKD60, and CKD90 (P  0.001) (Fig. 5C). Our
analysis of low-density lipoprotein (LDL) cholesterol concen-
trations (Fig. 5D) revealed significant between-group differ-
ences that were similar to those determined for total cholesterol
(P  0.0001). A progressive increase in LDL cholesterol was
found in groups CKD60 to CKD150 compared with CTRL
(P  0.01). Furthermore, CKD90 and CKD120 differed from
CKD30 (P  0.05), and CKD150 was significantly different
from all of the other CKD groups (P  0.01).
Hormonal Dosage
The analysis of plasma ACTH (Fig. 6A) using the Kruskal-
Wallis test revealed significant differences among the groups
(P  0.0001); significant increases were detected in CKD30,
CKD60, CKD90, and CKD150 compared with CTRL (P 
0.05). The concentrations of ACTH in CKD90 and CKD120
were significantly lower compared with those in CKD60 (P 
0.05). The concentration of corticosterone (Fig. 6B) exhibited
a group effect (P  0.0001); only CKD90 demonstrated a
difference compared with CTRL (P  0.05).
Sleep Parameters
Light period. SLEEP EFFICIENCY. The Kruskal-Wallis test re-
vealed significant differences among the groups (P  0.0001);
we observed a decrease in sleep efficiency in CKD30, CKD60,
and CKD90 compared with CTRL (P  0.05) (Fig. 7A).
AROUSALS. One-way ANOVA revealed a group effect (P 
0.0001); there were a greater number of arousals in all of the
CKD groups compared with CTRL (P  0.01) (Fig. 7B).
PARADOXICAL SLEEP. A group effect (P  0.0001) was ob-
served in the increased percentage of paradoxical sleep in
Fig. 4. Renal function. Blood urea (A), creatinine (B), sodium (C), and
potassium (D) concentrations in CTRL and CKD groups at different disease
time points. Values are expressed as means  SD. *P  0.05 compared with
CTRL. #P  0.05 compared with 30 days CKD (CKD30).
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CKD7 compared with CTRL (P  0.05) (Fig. 7C). Moreover,
an increase was detected in CKD7, CKD30, and CKD90
compared with CKD60 (P  0.05).
SLOW-WAVE SLEEP. A group effect (P  0.0001) was found
in the decreased percentage of slow-wave sleep in CKD7,
CKD30, and CKD90 compared with CKD60 (P  0.05)
(Fig. 7D).
WAKING. The Kruskal-Wallis test revealed differences
among the groups (P  0.0001); the percentage of time awake
was increased in CKD30, CKD60, and CKD90 compared with
CTRL (P  0.05) (Fig. 7E).
Dark period. SLEEP EFFICIENCY. A group effect (P  0.0001)
was observed in the increased sleep efficiency in CKD7,
CKD30, and CKD60 compared with CTRL (P  0.05) and in
the decreased sleep efficiency in CKD90 compared with CTRL
(P  0.05). Significant differences were also detected in
CKD7, CKD60, and CKD90 compared with CKD30 (P 
0.01). In addition, CKD30 and CKD90 differed significantly
from both CKD7 and CKD60 (P  0.01) (Fig. 8A).
AROUSALS. No significant differences were observed among
the groups (Fig. 8B).
PARADOXICAL SLEEP. A group effect (P  0.0001) was de-
tected in the increased percentage of paradoxical sleep in
CKD7 and CKD30 compared with CTRL (P  0.01). More-
over, a decrease was found in CKD60 and CKD90 compared
with both CKD7 and CKD30 (P  0.05) (Fig. 8C).
SLOW-WAVE SLEEP. A group effect (P  0.0001) was ob-
served in the decreased percentage of slow-wave sleep only in
CKD7 and CKD30 compared with CTRL (P  0.01). An
increase in slow-wave sleep was found in CKD60 and CKD90
compared with both CKD7 and CKD30 (P  0.05) (Fig. 8D).
WAKING. A group effect (P  0.0001) was observed in the
percentage of time awake in CKD7, CKD60, and CKD90,
which differed statistically from CTRL (P  0.05). A decrease
in the percentage of time awake was also determined in CKD7
and CKD60 compared with CKD30 (P  0.05). CKD90
differed statistically from CKD7, CKD30, and CKD60 (P 
0.01) (Fig. 8E).
Fig. 6. Hormonal parameters. Blood ACTH (A) and corticosterone (B) con-
centrations in CTRL and CKD groups at different disease time points. Values
are expressed as means  SD. *P  0.05 compared with CTRL. ¥P  0.05
compared with CKD90 and CKD120.
Fig. 5. Lipid profile. Blood triglycerides (A), total cholesterol (B), high-density
lipoprotein (HDL) cholesterol (C), and low-density lipoprotein (LDL) choles-
terol (D) concentration in CTRL and CKD groups at different disease time
points. Values are expressed as means  SD. A: *P  0.001 compared with
CTRL. #P  0.05 compared with CKD30, CKD60, CKD120, and CKD150. B
and D: *P  0.05 compared with CTRL. #P  0.05 compared with CKD30.
¥P  0.01 compared with CKD60, CKD90, and CKD120. C: *P  0.001
compared with CTRL. #P  0.001 compared with CKD30 and CKD90. ¥P 
0.001 compared with CKD60.
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A negative correlation was observed between the indepen-
dent variables creatinine, urea, MAP, HR, HDL, LDL, total
cholesterol, and ACTH and the dependent variable sleep effi-
ciency (Table 1). In the multiple-regression analysis, only
creatinine, urea, and MAP were significant determinants of
sleep efficiency, as predictors of diminished sleep quantity
(Table 1). A positive correlation was also observed between
the independent variables creatinine, urea, MAP, HR, HDL,
total cholesterol, and ACTH and the dependent variable num-
ber of arousals (Table 2). In the multiple-regression analysis,
only MAP was a significant determinant of arousals (Table 2),
as a predictor of diminished sleep quality.
Fig. 7. Sleep pattern in light period. Percentage of sleep efficiency (A), no. of arousals (B), percentage of paradoxical sleep (C), slow-wave sleep (D), and wake
(E) during the light period in CTRL and CKD groups at different disease time points. Values are expressed as means  SD. *P  0.05 compared with CTRL.
#P  0.05 compared with 7 days CKD (CKD7), CKD30, and CKD90.
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Fig. 8. Sleep pattern in dark period. Percentage of sleep efficiency (A), no. of arousals (B), percentage of paradoxical sleep (C), slow-wave sleep (D), and wake
(E) during the dark period in CTRL and CKD groups at different disease time points. Values are expressed as means  SD. A, B, and E: *P  0.05 compared
with CTRL. #P  0.05 compared with CKD30. ¥P  0.01 compared with CKD7 and CKD60. C and D: *P  0.01 compared with CTRL. ¥P  0.05 compared
with CKD7 and CKD30.
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DISCUSSION
The current study demonstrates the neurophysiological con-
sequences that occur during the progression of CKD and its
relationship with cardiovascular and metabolic changes in
uremic rats. The results showed that, with a gradual loss of
renal function, significant changes occurred in sleep homeosta-
sis, the cardiovascular system (hypertension), the biochemical
profile (dyslipidemia), and the endocrine system [hypothalamic-
pituitary-adrenal (HPA) activation]. Additionally, the study
revealed that the renal and cardiovascular impairment contrib-
uted initially to the alterations observed in the sleep architec-
ture of CKD animals. Nevertheless, in the long term, the poor
sleep quality found in uremic rats led to a sleep-loss condition
and might enhance the progression of disease.
The progressive loss of renal function during CKD is asso-
ciated with nontraditional risk factors such as renal anemia,
increase in uremic toxins, and excessive activation of the
sympathetic nervous system (SNS), which contribute to an
increase in morbidity and mortality (8). As a result of the SNS
hyperactivity, the sustained hypertension observed after induc-
tion of CKD is the main CKD comorbidity and the main cause
of death among renal patients. Moreover, the gradual increase
in the concentration of cholesterol in CKD rats is consistent
with previous findings concerning the metabolic changes that
occur in CKD animal models (10) and in renal patients (48).
CKD rats also presented an increase in plasma ACTH
without physiological changes in corticosterone, which indi-
cated a dysfunction of the HPA axis during disease progres-
sion. Although most studies have demonstrated HPA axis
integrity in patients with renal failure (20, 33), our findings
revealed a greater activation of the HPA axis and a high level
of stress. Therefore, it is necessary to emphasize that chronic or
prolonged stress responses may cause several disease states
(45) and contribute to important sleep pattern changes (42). In
fact, our results showed that the CKD rats demonstrated poor
sleep quality with a progressive decrease in sleep efficiency
and an increased number of arousals during the light period,
which is the primary sleeping period for rats. These findings
corroborate the results of clinical studies demonstrating that
CKD patients experience short and fragmented sleep that is
associated with a worse quality of life (9, 44). Our results
demonstrating the sleep problems that occurred since the be-
ginning of the disease (CKD30) are consistent with the findings
of De Santo and colleagues (14, 15), who reported that sleep
disorders occur even during the early stages of CKD, when
patients do not require therapies such as dialysis or kidney
transplantation.
Recently, Barmar and colleagues (9) have demonstrated via
actigraphy that CKD and hemodialysis patients demonstrate a
decrease in total sleep time and an increase in time awake
compared with healthy individuals. However, Parker et al. (44)
revealed that hemodialysis patients had a worse sleep quality
compared with CKD patients because a decrease in REM sleep
was observed only in the hemodialysis patients, suggesting
different etiologies for the observed sleep changes in CKD and
hemodialysis patients. Similarly, we did not observe marked
alterations in REM and slow-wave sleep in CKD rats compared
with CTRL. Because the CKD rats slept more during the dark
period and slept less in the light period compared with the
controls, our results suggest a trend of sleep-wake cycle rever-
sal, which is consistent with clinical data showing evidence of
a decreased total sleep time at night and increased symptoms of
excessive daytime somnolence in CKD patients (24, 25).
At CKD90, there was an important impairment in the sleep
architecture in which a decrease in sleep was observed in both
periods. This finding suggests that the end stage of renal disease
is accompanied by a significant worsening of sleep and of many
other parameters (urea, creatinine, cholesterol). It is important to
note that most studies designed to evaluate sleep disorders in
CKD patients utilize standardized questionnaires or actigraphy,
whereas polysomnography is the gold standard for the appropriate
diagnosis of sleep disorders and the assessment of sleep pattern. In
this sense, the sleep pattern similarities observed between the
disturbed sleep in CKD rats and the data of sleep disorders in
patients with CKD demonstrate that the current study can be a
reference for this model of sleep architecture in CKD.
The effects of uremic toxins in the central nervous system can
mediate the sleep problems associated with CKD (28). Millman et
al. (37) noted a slight but significant correlation between sleep
apnea syndrome and azotemia. In a more recent prospective study,
a strong association between high-efficiency dialysis and fewer
sleep disorders was found (54). As a late symptom of predialysis,
uremia has been classically associated with sleep-wake cycle
reversal (24, 25). Sleep disorders, which appear in 80% of
patients with chronic uremia, lead to daytime sleepiness, reduced
Table 2. Spearman’s correlation analysis and linear
multiple regression analysis of factors associated with
arousals as the dependent variable
Spearman’s
Correlation Analysis
Linear Multiple
Regression Analysis
r P  P
Creatinine, mg/dl 0.547 0.0001 0.463 0.644
Urea, mg/dl 0.549 0.0001 0.275 0.793
Mean arterial pressure, mmHg 0.696 0.0001 0.594 0.01
Heart rate, beats/min 0.557 0.0001 0.316 0.101
HDL cholesterol, mg/dl 0.332 0.05
LDL cholesterol, mg/dl 0.137 0.352
Total cholesterol, mg/dl 0.324 0.05
Tryglicerides, mg/dl 0.264 0.069
Corticosterone, ng/ml 0.380 0.061
ACTH, pg/ml 0.544 0.0001 0.089 0.607
Table 1. Spearman’s correlation analysis and linear
multiple regression analysis of factors associated with sleep
efficiency as the dependent variable
Spearman’s
Correlation Analysis
Linear Multiple
Regression Analysis
r P  P
Creatinine, mg/dl 0.668 0.0001 0.585 0.001
Urea, mg/dl 0.610 0.0001 0.578 0.01
Mean arterial pressure, mmHg 0.631 0.0001 0.412 0.05
Heart rate, beats/min 0.446 0.01 0.069 0.688
HDL cholesterol, mg/dl 0.532 0.0001 0.197 0.577
LDL cholesterol, mg/dl 0.354 0.01 0.467 0.479
Total cholesterol, mg/dl 0.542 0.0001 0.562 0.524
Tryglicerides, mg/dl 0.227 0.121
Corticosterone, ng/ml 0.278 0.179
ACTH, pg/ml 0.568 0.0001 0.236 0.155
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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mental acuity, and a deteriorating quality of life (57). Similarly to
our study, Kim et al. (28) demonstrated that animals with CKD
exhibit an activity profile reversal. During the disease course, they
observed a greater number of movements in CKD rats than in
controls, although this behavior was reversed in the dark. How-
ever, the absence or presence of movement is neither reliable nor
sufficient as a measure of the amount of sleep or the presence of
sleep disorders in uremic rats.
Some factors involved in sleep disruption could be the
individual peripheral oscillators, which are influenced by the
master circadian pacemaker in the suprachiasmatic nucleus.
These individual peripheral oscillators are disturbed in CKD
patients due to mainly an impaired partial oxygen pressure and
blood flow in the kidney (32, 38, 56). For example, some
studies have demonstrated that the physiological nocturnal rise
in melatonin is absent in hemodialysis patients (27, 31). Be-
cause melatonin is an important marker of the circadian timing
system (31) and its release can be affected by stress, interacting
in this condition with adrenal steroid secretion (46), it is
possible that this hormone could also be involved in the sleep
disturbances observed in CKD rats. Additionally, circadian
rhythms play an important role in the regulation of cardiovas-
cular physiology (21, 40); thus, circadian dysregulation can
induce hypertension (19) and renal disease (36).
In addition to melatonin, it has also been suggested that
altered cytokine levels have a role in sleep disorders (17).
Chronic inflammation, as determined by altered cytokine lev-
els, is highly prevalent in patients with end-stage renal disease
(16). Erten et al. (16) have demonstrated an association be-
tween sleep complaints and proinflammatory cytokines (IL-1
in particular) in hemodialysis patients. Similarly, we have
found an increase in the circulating levels of the proinflamma-
tory cytokines IL-1, IL-6, and TNF- in CKD rats (Hirotsu,
unpublished data). These cytokines, which are produced by
peripheral blood mononuclear cells in the bloodstream, work
as pyrogenic signals in specific centers within the central
nervous system. Such signals induce the synthesis of prosta-
glandins, which constitute the central mediators of the coordi-
nated response that leads to a rise in the core body temperature,
thus contributing to the circadian disorganization (31).
It is important to stress that the changes observed in the sleep
pattern of uremic rats are more than solely a consequence of
the disease. They also represent an additional risk factor for
CKD exacerbation. Chronically, the establishment of sleep
disorders leads to sleep deprivation, which can induce adverse
physiological effects, including hypertension, activation of the
SNS, impairment of glucose control, and increased inflamma-
tion (5). A variety of epidemiological studies have also sug-
gested an association between self-reported sleep duration and
long-term health. Individuals who report an increased or a
reduced sleep duration have a moderately increased risk for
all-cause mortality, cardiovascular disease, and the develop-
ment of symptomatic diabetes (55). Therefore, sleep is clearly
important for a healthy lifestyle in CKD. An adequate sleep
duration and quality are important for the normal functioning
of daily metabolic and hormonal processes (55) in CKD.
To the best of our knowledge, the overall approach and
neurophysiological relationships presented herein have not
been reported previously. The multiple linear regression anal-
ysis showed that the renal parameters (urea and creatinine) and
the hypertension were predictive factors for a worsened sleep
quantity and quality. However, it is noteworthy that changes in
the HPA axis, HR, and cholesterol were associated with
changes in the sleep architecture. Based on these results, it can
be inferred that the changes in renal function and blood
pressure observed during CKD progression were important
factors and contributed to the impaired sleep quality but not via
a cause-effect relationship. The modifications of the cardiovas-
cular system, lipid profile, and HPA axis occurred before a
significant loss of kidney function, which suggests that the
changes in sleep architecture observed after CKD onset may
result from the synergistic interaction of many factors inherent
to the disease. Similarly, the disrupted sleep pattern in CKD
animals becomes an important factor in the exacerbation of
renal disease because the chronic condition of poor sleep
quality interferes with the body and life as a whole.
Considering that sleep disorders are common in patients with
CKD and do not receive extensive clinical and scientific interest,
it is important to understand the pathogenic mechanisms that
govern the initiation and progression of sleep disorders in CKD.
Thus our results highlight the need for a greater consideration of
the polysomnography in the clinical follow-up of renal patients to
assess and treat potential sleep disorders and thereby improve
patient quality of life. Because the disturbed sleep in CKD rats is
similar to that observed in patients with CKD, the present study
can be a key reference for this new model of sleep disorders in
CKD in humans and in mammals.
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